Navigation Links
Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2011 Earnings Release Date and Teleconference
Date:10/8/2010

EXTON, Pa., Oct. 8 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that it will release its earnings results for its first quarter ended September 30, 2010 at 7:30 A.M. Eastern Time on Thursday, October 21, 2010.  

Joe Kaufmann, President and CEO, will be hosting a teleconference discussing the earnings results on Thursday, October 21, 2010 at 9:00 A.M. Eastern Time.  

To participate in the teleconference call, dial 1-612-332-0335. The teleconference call will also be available for replay starting Thursday, October 21, 2010 at 11:00 A.M. Eastern Time through Thursday, October 28, 2010 at 11:59 P.M. Eastern Time by dialing 1-800-475-6701 with an access code of 174247.

Individuals interested in listening to the teleconference may also do so over the Internet at www.kenseynash.com.  To listen to the live teleconference call, please go to the www.kenseynash.com website and choose the Investor Relations page.  Please allow 15 minutes prior to the start of the call to register and download and/or install any necessary software.  A replay of the teleconference will be archived on the www.kenseynash.com website and may be accessed following the teleconference.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology.  The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials.  The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopaedic, sports medicine, spine, e
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
2. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
4. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
6. Kensey Nash Announces $30 Million Share Buyback
7. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
8. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
9. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
10. Kensey Nash to Present at the Ninth Annual JMP Securities Research Conference
11. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015  Eli Lilly and Company (NYSE: LLY ) ... tender offer for up to $1.6 billion aggregate principal amount ... of notes who tendered, and did not validly withdraw, their ... City time, on May 27, 2015 (the early ... are eligible to receive the total consideration. The total consideration ...
(Date:5/28/2015)... May 28, 2015 Zimmer Holdings, Inc. (NYSE ... finalized agreements with buyers to divest in ... Knee System assets, Biomet Discovery® Elbow System assets and ... furtherance of Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... to work constructively with the Bureau of Competition Staff ...
(Date:5/28/2015)... , May 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ... for the second quarter and three and six months ended ... Canadian dollars and in accordance with International Financial Reporting Standards ... recorded a net loss of $5.9 million ($0.35 per common ... compared to a net loss of $0.4 million ($0.03 per ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... 8, 2011 /PRNewswire-Asia/ -- China Medicine Corporation (Other ... leading manufacturer, developer and distributor of Western pharmaceuticals, ... in the People,s Republic of China, today announced ... China Medicine Corporation, after consultation with and upon ...
... Steve Beshear announced yesterday that most of Kentucky,s Medicaid ... state $375 million. In modernizing the state,s Medicaid pharmacy ... by pharmacy benefit managers (PBMs) to lower prescription drug ... said. "Governor Beshear has done the right ...
Cached Medicine Technology:China Medicine Corporation to Restate Financial Statements for 2006 and 2007 2China Medicine Corporation to Restate Financial Statements for 2006 and 2007 3Modernizing Medicaid Rx with 'Innovative' PBM Tools Will Help Kentucky Save $375 Million 2
(Date:5/28/2015)... 2015 External Counterpulsation (EECP/ECP) has been ... the United States. There are a growing number of ... experience symptoms of angina and these patients are often ... bypass surgery. , “No option” patients are a sizable ... disease that is considered unacceptable for heart stent or ...
(Date:5/28/2015)... Cosmetic Town Journal is a national ... alike. You can find information on a variety of ... Readers can directly connect to the doctor of their ... ground up. , The continued addition of doctors and ... grow and getting it closer to becoming an all ...
(Date:5/28/2015)... Today the National Resident Matching Program (NRMP®) released ... Residency Match®. A record-number 30,212 positions were placed ... matching algorithm was processed. Of the 1,306 positions ... Supplemental Offer and Acceptance Program® (SOAP®) leading up to ... outcome of the 2015 Main Residency Match. A record ...
(Date:5/28/2015)... Sierra Madre, CA (PRWEB) May 28, 2015 ... providing superior outpatient wound center management for a decade with ... a partnership was formed between USC and Wound Care Advantage ... team was recognized for a drop in the ... percent. , Wound healing is a complex undertaking that ...
(Date:5/28/2015)... The partners of Urgent Care of ... Dr. Alicia Almendral as their chief provider for advanced ... the newly opened facility’s plan to offer all of ... , Dr. Almendral is a board certified physician who ... cosmetic enhancement techniques. Her areas of expertise include Botox, ...
Breaking Medicine News(10 mins):Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:New York Cosmetic Doctors Now in Cosmetic Town 2Health News:New York Cosmetic Doctors Now in Cosmetic Town 3Health News:NRMP Releases Results and Data: 2015 Residency Match: Record Number of Positions Filled 2Health News:NRMP Releases Results and Data: 2015 Residency Match: Record Number of Positions Filled 3Health News:USC Verdugo Hills Hospital Wound Care Team Provides Outstanding Healing Results 2Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2
... , , HARRISBURG, Pa., July ... received free dental care, valued at nearly $160,000, in the ... United Concordia Dental. , , ... provide free preventive services to those who cannot afford dental ...
... , INDIANAPOLIS, July 23 Today, ... that the U.S. Food and Drug Administration (FDA) has approved ... origin) injection] to treat osteoporosis associated with sustained, systemic glucocorticoid ... Glucocorticoid therapy is the most common cause of secondary osteoporosis, ...
... Cancer stem-like cells have been implicated in the ... at Cedars-Sinai Medical Center,s Maxine Dunitz Neurosurgical Institute have ... these "mother" cells to generate new tumors in laboratory ... a possible strategy in the fight against malignant and ...
... , , , , ... Program (NCDP), a program of Novo Nordisk, and several member associations today ... and treatment of diabetes, one of the nation,s most pervasive and costly ... , In an open letter to the President and ...
... , , SAN DIEGO, ... ) today announced that it has priced an underwritten public ... price of $7.50 per share. Net proceeds, after estimated underwriting ... million. Orexigen has granted the underwriter a 30-day option to ...
... 23 At the 2009 American Association of Physicists ... California, Elekta will demonstrate how the company,s comprehensive VMAT ... care with precision and ease. , , ... radiation treatments, Elekta booth 423 will highlight treatment planning ...
Cached Medicine News:Health News:More than 1,000 Underinsured and Uninsured Individuals Receive Free Dental Care 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 4Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 5Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 6Health News:Study provides documentation that tumor 'stem-like cells' exist in benign tumors 2Health News:Study provides documentation that tumor 'stem-like cells' exist in benign tumors 3Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 2Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 3Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 3
Reusable shielded cable...
... A OIA MAX test delivers excellent sensitivity ... Strep with a simple, easy-to-use test that ... of performance, speed, and ease-of-use enables you ... overall costs for diagnosing and treating patients ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... The FLU OIA test is a ... diagnosis of Influenza A and B with ... answer in just over 15 minutes. Assay ... specimen flexibility, and performance equivalent to 14-day ...
Medicine Products: